Andrew Geall, Ph.D.

Chief Development Officer

Dr. Andrew Geall is Replicate Bioscience's Chief Development Officer and co-founder. With over 20 years of experience in developing drug delivery systems, he is a pioneer in mRNA vaccines and nucleic acid delivery. He holds 505 patent applications and 203 issued patents in multiple jurisdictions.

Before Replicate, he served as Chief Scientific Officer at Precision NanoSystems Inc., where he worked on creating nanoparticle medicines using LNP delivery systems and microfluidic formulation platform. He also held positions at Avidity Biosciences and Novartis, where he led the development of mRNA vaccines platform and led the Global siRNA Formulation Team. Dr. Geall obtained his pharmacy degree and a PhD from the University of Bath in the UK.

On demand Webinar mRNA – POWERING LIFE CHANGING THERAPIES

In this webinar, join industry experts to learn about strategies to accelerate mRNA therapies and enable scalability and process efficiency from preclinical to commercial.

Scroll to Top